350 related articles for article (PubMed ID: 32165025)
1. Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel.
Cury-Martins J; Eris APM; Abdalla CMZ; Silva GB; Moura VPT; Sanches JA
An Bras Dermatol; 2020; 95(2):221-237. PubMed ID: 32165025
[TBL] [Abstract][Full Text] [Related]
2. The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies.
Balagula Y; Rosen ST; Lacouture ME
J Am Acad Dermatol; 2011 Sep; 65(3):624-635. PubMed ID: 21777992
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
4. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
[TBL] [Abstract][Full Text] [Related]
5. Management of dermatologic toxicities.
Lacouture ME
J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):686-9. PubMed ID: 25995431
[TBL] [Abstract][Full Text] [Related]
6. An overview of acute gastrointestinal side effects of systemic anti-cancer therapy and their management.
Smith P; Lavery A; Turkington RC
Best Pract Res Clin Gastroenterol; 2020; 48-49():101691. PubMed ID: 33317796
[TBL] [Abstract][Full Text] [Related]
7. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study.
Barrios DM; Phillips GS; Freites-Martinez A; Hsu M; Ciccolini K; Skripnik Lucas A; Marchetti MA; Rossi AM; Lee EH; Deng L; Markova A; Myskowski PL; Lacouture ME
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1340-1347. PubMed ID: 31856311
[TBL] [Abstract][Full Text] [Related]
8. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
Tang N; Ratner D
Dermatol Surg; 2016 Jan; 42 Suppl 1():S40-8. PubMed ID: 26730973
[TBL] [Abstract][Full Text] [Related]
9. Targeted agents: management of dermatologic toxicities.
Burtness B
J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):793-6. PubMed ID: 24853219
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy in oncology patients and skin: Pharmaceutical and dermocosmetic management.
Varvaresou A; Iakovou K; Mellou F; Myrogiannis D; Papageorgiou S
J Cosmet Dermatol; 2020 Apr; 19(4):782-788. PubMed ID: 31769600
[TBL] [Abstract][Full Text] [Related]
11. Dermatologic Reactions to Targeted Therapy: A Focus on Epidermal Growth Factor Receptor Inhibitors and Nursing Care.
Barton-Burke M; Ciccolini K; Mekas M; Burke S
Nurs Clin North Am; 2017 Mar; 52(1):83-113. PubMed ID: 28189168
[TBL] [Abstract][Full Text] [Related]
12. Tattoo Reactions Associated with Targeted Therapies and Immune Checkpoint Inhibitors for Advanced Cancers: A Brief Review.
Kluger N
Dermatology; 2019; 235(6):522-524. PubMed ID: 31387093
[No Abstract] [Full Text] [Related]
13. Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology.
Dreno B; Bensadoun RJ; Humbert P; Krutmann J; Luger T; Triller R; Rougier A; Seité S
J Eur Acad Dermatol Venereol; 2013 Sep; 27(9):1071-80. PubMed ID: 23368717
[TBL] [Abstract][Full Text] [Related]
14. Skin Toxicities: Common Side Effect.
Mahon SM; Carr E
Clin J Oncol Nurs; 2021 Dec; 25(6):32. PubMed ID: 34800129
[TBL] [Abstract][Full Text] [Related]
15. Management of Immunotherapy-Related Toxicities, Version 1.2019.
Thompson JA; Schneider BJ; Brahmer J; Andrews S; Armand P; Bhatia S; Budde LE; Costa L; Davies M; Dunnington D; Ernstoff MS; Frigault M; Hoffner B; Hoimes CJ; Lacouture M; Locke F; Lunning M; Mohindra NA; Naidoo J; Olszanski AJ; Oluwole O; Patel SP; Reddy S; Ryder M; Santomasso B; Shofer S; Sosman JA; Wahidi M; Wang Y; Johnson-Chilla A; Scavone JL
J Natl Compr Canc Netw; 2019 Mar; 17(3):255-289. PubMed ID: 30865922
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
Hammond-Thelin LA
Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
[TBL] [Abstract][Full Text] [Related]
17. Skin adverse events in recently approved targeted therapies in solid malignancies.
Habre M; Salloum A; Habre SB; Abi Chebl J; Dib R; Kourie HR
Future Oncol; 2019 Jan; 15(3):331-343. PubMed ID: 30523696
[TBL] [Abstract][Full Text] [Related]
18. Skin Toxicity: Clinical Summary of the ONS Guidelines™ for Cancer Treatment-Related Skin Toxicity.
Wiley K; Ebanks GL; Shelton G; Strelo J; Ciccolini K
Clin J Oncol Nurs; 2020 Oct; 24(5):561-565. PubMed ID: 32945804
[TBL] [Abstract][Full Text] [Related]
19. The Role of Oncodermatology in the Care of Patients Receiving Cancer Therapy.
Skripnik Lucas A; Ciccolini K
Semin Oncol Nurs; 2017 Nov; 33(4):393-401. PubMed ID: 28943034
[TBL] [Abstract][Full Text] [Related]
20. [Dermatological reactions in patients in antineoplastic therapy].
Prasad SC; Vestergaard H; Bygum A
Ugeskr Laeger; 2014 May; 176(11):. PubMed ID: 25096844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
